NASH Market Insight and Landscape report

Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development of effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. Thelansis "NASH – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape of disease overview, pathogenesis, and country/region specific current treatment practice

The global non-alcoholic steatohepatitis (NASH) market is estimated ~$2,579 million in 2015, and is expected to cross $39,596 million by the end of 2030, growing at a CAGR of 21.9% from 2015 to 2030 (15 years of markets projections; four years of historical data, one year of current and eleven years of future market projections). North America, ASIA and Europe are the major region reported with a high prevalence & diagnosed patient pool, however US and Canada mutually contributed ~ 52.34 % of the total revenue followed by EU5(Germany, UK, France, Italy and Spain) with 23.67%. NASH is projected to be the leading cause of liver transplantation in the USA in the coming years which will increase overall disease burden within the space. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

The disease segmentation of NASH patient pool further classified and segregated into different stages fibrosis (F0, F1, F2, F3 & F4-Cirrhosis) includes historical, current and projected epidemiology.

The overall market for NASH has been defined on the basis of country-specific current clinical practice includes symptomatic and off-label therapies, patient share and disease burden (treatment cost, compliance, and market access) has been translated into market.

Emerging therapies:
The developmental pathway for therapeutic agents involves navigating multiple complexities that include the non-linear, heterogeneous nature of disease progression, and the limitations in identifying clinically relevant outcomes. The design of each phase of a clinical trial for a potential therapeutic agent is strongly influenced by the drug’s mechanism of action, characteristics of the patient population (F0, F1, F2, F3 & F4-Cirrhosis) influence by trial design. Currently there are multiple players involved in the designing and development of novel therapies such as: Elafibranor (GFT505) : Genfit, Obeticholic Acid (OCA): Intercept Pharmaceuticals, Cenicriviroc (CVC): (Allergan- Tobira), GS-9674, GS-0976: Gilead Sciences, BMS-98603: BMS, MSDC-0602K: Cirius Therapeutics, Emricasan (IDN-6556): Conatus Pharmaceuticals, NGM282: NGM Biopharmaceuticals, IMM-124E : Immuron, Selonsertib: Gilead Sciences, Aramchol_005: Galmed, GR-MD-02: Galectin Therapeutics

Annual cost of therapy:
Due to lack of treatment options, advanced liver diseases associated with NAFLD will be doubles over coming years. Direct healthcare costs in the USA the annual cost of care per NASH patient with private/ public insurance ranges between USD 3, 367 to USD 8,750 considering current treatment options. These costs are significantly higher in case of patients with control other metabolic comorbidities conditions. The European nations majorly EU5 countries are having the cost burden in similar line, however the reference pricing system and generic entry plays a role in controlling the cost burden

http://www.thelansis.com

Contact Person: Prasoon Narang
Contact NO.:+1-13023803552

Thelansis Knowledge Partners
183 Asylum Street Hartfort
CT-06103, US

This release was published on openPR.